Search

Displaying results 3491 - 3500 of 4238 in total
  1. Drug

    2'-Fucosyllactose

    go.drugbank.com/drugs/DB16052
    Investigational

    2'-Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-tnf Therapy).

  2. Drug

    Afelimomab

    go.drugbank.com/drugs/DB04956
    Experimental

    Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.

  3. Drug

    PM02734

    go.drugbank.com/drugs/DB05158
    Investigational

    PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types: breast, colon, pancreas, lung and prostate, among others.

  4. Drug

    KC706

    go.drugbank.com/drugs/DB05157
    Investigational

    KC706 holds potential to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and cardiovascular disease.

  5. Drug

    Fiztasovimab

    go.drugbank.com/drugs/DB24033
    Investigational

    Fiztasovimab, also known as NPC‐21 and EV2038, is a monoclonal antibody.

  6. Drug

    Fentanyl

    go.drugbank.com/drugs/DB00813
    ApprovedIllicitInvestigationalVet approved

    Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L66...

  7. Drug

    Tosedostat

    go.drugbank.com/drugs/DB11781
    Investigational

    It has demonstrated anti-tumour activity in a number of models of cancer, both as a single agent and in synergy with cytotoxic agents such as carboplatin and paclitaxel.

  8. Drug

    CTS-21166

    go.drugbank.com/drugs/DB06073
    Investigational

    CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. … In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability

  9. Drug

    Atipamezole

    go.drugbank.com/drugs/DB11481
    InvestigationalVet approved

    It has also been undergone research as a potential anti-Parkinsonian drug for humans.

  10. Drug

    Sodium tripolyphosphate

    go.drugbank.com/drugs/DB11493
    InvestigationalVet approved

    It is used as a component of a wide range domestic and industrial products, particularly detergents.